We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Telix seeks European approval of glioma imaging agent

Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions in people with glioma. “We see a compelling opportunity in Europe to broaden...

Source: Pharmacy Times articles Post Content Read More

Elenagen helps women with ovarian cancer live 1 year longer

Adding Elenagen, Curelab Oncology’s experimental anticancer medication, to gemcitabine chemotherapy may help women with treatment-resistant ovarian cancer live significantly longer. Those are the results of a small clinical trial, conducted at a single center in...

Blood test helps predict myeloma relapse risk without biopsy

A new, ultrasensitive blood test checks for cancer cells remaining in the body after multiple myeloma treatment using blood samples instead of more invasive bone marrow biopsies, helping doctors assess relapse risk and monitor treatment response. Quest Diagnostics...

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Source: Myeloma : nature.com subject feeds Post Content Read More
Latest Data

Latest Publications

Email

info@myeloma360.com

bahisliongalabet1xbet